AstraZeneca shares rise on tax bill boost
AstraZeneca has raised its profit outlook for the year after reaching an agreement with British and US authorities that will see it pay less tax than it had budgeted for.
Cash back: Fillip to the company's profit line as it faces increasing challenges
Having made provisions for $2.3bn of tax, the settlement of matters dating back more than a decade means Britain's second-biggest drugmaker will pay a only $1.1bn in 2011 to resolve US transfer pricing issues.
As a result, AstraZeneca expects 2011 core earnings to be between $6.90 and $7.20 per share, up from the $6.45 to $6.75 range previously indicated.
There will be a $500m boost to earnings in the first quarter and the effective tax rate for the year will be some 6 percentage points lower than thought, at around 21%.
The news is a fillip to the company's profit line at a time when it faces increasing challenges to some of its top-selling drugs from generic competition.
Shares in AstraZeneca are up 25.5p (0.9%) at 2,899.5p so far this morning, modestly outperforming a 0.5% increase in the European drugs sector.
AstraZeneca could look slightly more attractive with the removal of the liability said Panmure Gordon analyst Savvas Neophytou, who rates the stock a 'buy', although big pharmaceutical companies do not seem to be looking for major acquisitions just now, he added.
The latest settlement follows an earlier agreement with the British tax authorities on transfer pricing in February 2010, which also resulted in payments that were less than had been provided for, resulting in increased 2010 earnings.
Transfer pricing concerns the price at which one unit of a group sells goods or services to another unit of the same group. Such practices are receiving increased attention as tax authorities around the world seek to limit any abuse of intra-company transfers of expenses or profits.
Most watched Money videos
- BMW's Vision Neue Klasse X unveils its sports activity vehicle future
- Dean Dunham: Entitled to comparable replacement concert tickets?
- 'Now even better': Nissan Qashqai gets a facelift for 2024 version
- Land Rover unveil newest all-electric Range Rover SUV
- Blue Whale fund manager on the best of the Magnificent 7
- Tesla unveils new Model 3 Performance - it's the fastest ever!
- 2025 Aston Martin DBX707: More luxury but comes with a higher price
- Mini celebrates the release of brand new all-electric car Mini Aceman
- Mini Cooper SE: The British icon gets an all-electric makeover
- Skoda reveals Skoda Epiq as part of an all-electric car portfolio
- Volvo's Polestar releases new innovative 4 digital rearview mirror
- Mercedes has finally unveiled its new electric G-Class
- BUSINESS LIVE: UK GDP grows 0.6%; IAG profits take off;...
- Vodafone told to boost security as £15bn Three merger is...
- My favourite 20 new cars for under £20,000 - by the...
- Bank of England paves way for Britain to cut interest...
- Takeover target Wood Group hit by slump in revenues as...
- Should the Bank of England have cut interest rates...
- How criminals could use AI to scam Britons - and what can...
- Rightmove expects weaker ad revenue growth as more...
- BA owner IAG profits climb more than sevenfold
- ITV hopes for summer ad boom as it continues to reel from...
- SMALL CAP MOVERS: Light Science Technologies sales flourish
- Cameron left red-faced as Greensill sues Government over...
- BBVA goes directly to shareholders as it steps up bid for...
- Bailey pulls his punches on interest rates yet...
- MARKET REPORT: North Sea giant Harbour closes in on £9bn...
- Some estate agents only put forward offers from buyers...
- Families with TWO retired generations will surge to one...
- My uncle has £14,000 in Dart Charge fines despite trying...